Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell popu... bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers. Mehr anzeigen
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on...
Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System...
Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician offices signed increased 75% over Q2 2024...
Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today...
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement PR Newswire JERSEY CITY, N.J., Oct. 21, 2024 JERSEY...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed its...
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement PR Newswire JERSEY CITY, N.J., Oct. 18, 2024 JERSEY...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has entered...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.15 | -14.0186915888 | 1.07 | 1.29 | 0.88 | 230306 | 1.03461346 | CS |
| 4 | -0.26 | -22.0338983051 | 1.18 | 1.29 | 0.8305 | 157197 | 1.01735695 | CS |
| 12 | -0.97 | -51.3227513228 | 1.89 | 2.2372 | 0.8305 | 149728 | 1.30071472 | CS |
| 26 | -0.98 | -51.5789473684 | 1.9 | 2.9893 | 0.8305 | 130001 | 1.63845774 | CS |
| 52 | -0.7 | -43.2098765432 | 1.62 | 3.62 | 0.8305 | 137702 | 1.98538486 | CS |
| 156 | -7.48 | -89.0476190476 | 8.4 | 15.55 | 0.8305 | 479721 | 3.71024327 | CS |
| 260 | -7.48 | -89.0476190476 | 8.4 | 15.55 | 0.8305 | 479721 | 3.71024327 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
